Almirall (LTS:0O9B) Institutional Ownership : 15.54% (As of Dec. 15, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Almirall Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Almirall's institutional ownership is 15.54%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Almirall's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Almirall's Float Percentage Of Total Shares Outstanding is 0.00%.

Almirall Institutional Ownership Historical Data

The historical data trend for Almirall's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall Institutional Ownership Chart

Almirall Historical Data

The historical data trend for Almirall can be seen below:

	2024-02-29	2024-03-31	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30
Institutional Ownership	13.53	13.73	14.03	14.34	14.87	15.34	15.61	15.31	15.55	15.54

Almirall Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Almirall Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (LTS:0O9B) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ALM:Spain E2Z:Germany

Address

Ronda General Mitre 151, Barcelona, ESP, 08022

Website

http://www.almirall.es

Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall Headlines

No Headlines